检索结果-南通市图书馆

Efficacy and safety of 0.4 percent sodium hyaluronate for endoscopic submucosal dissection of gastric neoplasms

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第20期19卷 3069-3076页

作者： Young Dae Kim Jun Lee Ju Yeon Cho Seok Won Kim Seong hwan Kim Young Kwan Cho Jin Seok Jang Ji Sun Han Joo Young Cho Division of Gastroenterology and Hepatology Department of Internal MedicineMedical SchoolChosun UniversityGwangju 501-717South Korea Department of Internal Medicine Eulji HospitalEulji UniversitySeoul 139-872South Korea Department of Internal Medicine Dong A University College of MedicineBusan 602-715South Korea Department of Internal Medicine Institute for Digestive ResearchDigestive Disease CenterSoonchunhyang University College of MedicineSeoul 140-743South Korea

AIM:To evaluate the efficacy and safety of sodium hyaluronate solution(SH) in endoscopic submucosal dissection(ESD) of gastric ***:A prospective multicenter randomized,double blind,controlled trial was designed and utilized in this study.A total of 76 patients with 5-20 mm sized gastric neoplasms were enrolled at three academic hospitals in South Korea from June 2011 to October *** were randomly assigned to the 0.4% sodium hyaluronate or control *** lesions underwent endoscopic *** was performed with 0.4%SH and normal saline(NS) solution for submucosal *** was assessed using en bloc resection and the number of additional *** evaluation variables were the volume of injection material,steepness of mucosal elevation,bleeding rate,procedural time and operator ***,the safety was assessed by analyzing adverse events during the ***:The usefulness rate in the 0.4%SH group and the controlled group had statistically significant difference under intention to treat(ITT) analysis(90.91% vs 61.11% P = 0.0041).Under per protocol(PP),the usefulness rate is statistically significant different(93.10% vs 61.76%,P = 0.0036).The difference in volume of the solution injected between 0.4%SH group and the controlled group and NS group was also statistically significant under intention to treat and per protocol analysis(ITT:0.03 ± 0.02 mL vs 0.06 ± 0.03 mL,P = 0.0003,PP:0.03 ± 0.02 mL vs 0.06 ± 0.03 mL,P = 0.0004).Satisfaction above the grade good was significantly higher in the SH group under intention to treat and per protocol analysis(ITT:90.91% vs 61.11%,P = 0.0041,PP = 93.11% vs 61.77%,P = 0.0022).Adverse events above grade 3 were not noticed in either *** adverse events were treated and were judged as not associated with the submucosal injection ***:0.4%SH solution is a safe and effective agent that doesn't cause any significant adverse events and is useful for submucos

关键词： Sodium hyaluronate Endoscopic submucosal dissection Gastric neoplasm Endoscopic mucosal resection

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国乡村的农家乐旅游与竞争空间

原生态民族文化学刊 2019年第5期11卷 130-143页

作者：朴忠焕罗士泂李飔飏(译) 赵旭东(校) 庆北国立大学考古人类学系韩国大邱427-724 中国人民大学人类学研究所北京100872

过去的20年里,一种独特的乡村旅游形式在中国蓬勃发展起来。这一中国式的乡村旅游形式有一个时兴的称呼,叫作“农家乐”。它是指农民在自己的农家院里招待都市客人,为他们提供具有典型的乡土、家庭、真实、环保、健康和传统等象征意义... 详细信息

过去的20年里,一种独特的乡村旅游形式在中国蓬勃发展起来。这一中国式的乡村旅游形式有一个时兴的称呼,叫作“农家乐”。它是指农民在自己的农家院里招待都市客人,为他们提供具有典型的乡土、家庭、真实、环保、健康和传统等象征意义的乡野食物和居住环境。农家乐农家院的空间为城乡之间的遭遇、社会边界的制造和农民主人与都市客人之间的身份认同政治提供了鲜明可观的场域。通过关注农家乐农家院的空间,探讨了都市客人和农民主人如何想象和体验中国乡村,以及在改革开放之后意义场域与城乡权力关系均处于快速变动的状态下,这一空间是如何将多样的社会进程、散乱的体系和物质与象征力量联系起来的。

关键词：农家乐旅游竞争空间现代性场所制造城乡身份认同政治

Potential of Natural Killer Cell Enriched Conditioned Media for Skin Care and Anti-Aging

在线全文

学校读者我要写书评

暂无评论

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis

Journal of Cosmetics, Dermatological Sciences and Applications（化妆品、皮肤病及应用期刊） 2021年第2期

作者： dong Soo Kim dong Ju Kim Hyun Pyo Kim Sung hwan hwang Jung Hwa Kang

来源：评论

学校读者我要写书评

暂无评论

Cancer Communications 2021年第3期41卷 275-278页

作者： Jun Ho Yi Seok Jin Kim Dok Hyun Yoon Cheolwon Suh Myung Hee Chang Deok hwan Yang Jae-Cheol Jo Shin Young Hyun Hyeon-Seok Eom Jeong-Ok Lee Ji Hyun Kwon Sang Hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung Kim Dae Sik Kim Ji Hyun Lee Sung Yong Oh Hun Mo Ryoo Hyo Jung Kim Won Seog Kim Division of Hematology-Oncology Department of MedicineChung-Ang UniversityDongjak-guSeoul 06973Korea Division of Hematology and Oncology Department of MedicineSamsung Medical Center Sungkyunkwan University School of MedicineGangnam-guSeoul 06351Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Korea National Health Insurance Corporation Ilsan Hospital Ilsandong-guGoyang 10444Korea Department of Hemato-Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolHwasunGwangju 58128Korea Department of Hematology and Oncology Ulsan University HospitalUniversity of Ulsan College of MedicineDong-guUlsan 44033Korea Department of Internal Medicine Yonsei University Wonju College of MedicineGangwon-DoWonju 26426Korea Department of Internal Medicine National Cancer CenterGoyang-si Gyeonggi-doGoyang 10408Korea Department of Internal Medicine Seoul National University Bundang HospitalBundang-guSeongnam 13620Korea Department of Internal Medicine ChungBuk National University HospitalChungbukCheongju 28644Korea Department of Internal Medicine Jeju National University HospitalJeju National University School of MedicineJeju 63241Korea Department of Hematology-Oncology Wonkwang University HospitalIksan-daeroIksan 54538Korea Department of Internal Medicine Jeonbuk National University Medical SchoolJeollabuk-doJeonju 54907Korea Division of Hematology-Oncology Department of Internal MedicineSoonchunhyang University College of MedicineBucheon HospitalWonmi-guBucheon 14584Korea Division of Hematology-Oncology Department of Internal MedicineKorea University Guro HospitalGuro-guSeoul 08308Korea Division of Hematology-Oncology Department of Internal MedicineDong-A University College of MedicineSeo-guBusan 49201Korea Department of Internal Medicine Division of Hematology-Oncology Catholic University of DaeguDaegu 42472Korea Division of Hematology-Oncology Department of Internal MedicineHallym U

Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease.

关键词： patients relapse lymphoma

基于核苷酸测序揭示辣椒CMS线粒体基因组结构变异

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

辣椒杂志 2014年第3期12卷 39-50页

作者： Yeong Deuk Jo Yoomi Choi dong-hwan Kim Byung-dong Kim Byoung-Cheorl Kang 刘峰郑井元张西露戴雄泽 Department of Plant Science Plant Genomics and Breeding InstituteInstitute of Green BioScience and TechnologySeoul National University Advanced Radiation Technology Institute Korea Atomic Energy Research Institute Department of Molecular Biosciences The University of Texas at Austin Department of Plant SciencePlant Genomics and Breeding Institute Institute of Green BioScience and TechnologySeoul National University 湖南省蔬菜研究所

背景:胞质雄性不育(CMS)是由于线粒体基因组突变导致无功能性花粉产生的一种现象。对CMS和非CMS线粒体基因组的比较分析,揭示线粒体基因组间结构差异及因重组导致的广泛性重排具有重要意义。然而,在辣椒中与CMS相关的线粒体基因组结构及... 详细信息

背景:胞质雄性不育(CMS)是由于线粒体基因组突变导致无功能性花粉产生的一种现象。对CMS和非CMS线粒体基因组的比较分析,揭示线粒体基因组间结构差异及因重组导致的广泛性重排具有重要意义。然而,在辣椒中与CMS相关的线粒体基因组结构及DNA重排机制仍不清楚。结果:获得了辣椒CMS FS4401(507 452 bp)和可育系Jeju(511 530 bp)线粒体完全基因组序列。并对辣椒、烟草线粒体基因组进行了比较分析,发现其均存在广泛的DNA重排和低保守性的非编码DNA区。FS4401和Jeju线粒体基因组比较发现,除了FS4401线粒体基因组中多了一个atp6(ψatp6-2)基因拷贝外,线粒体所有蛋白编码基因都一致。在基因组结构方面,发现两个线粒体基因组上的18个同线性序列区在基因组上存在重排,这些同线性序列区之间的序列总长度分别为30 380(FS4401)和17 847 bp(Jeju)。此前报道的CMS候选基因、orf507和ψatp6-2均位于FS4401最大特异序列片段的边界,在此区间大量的短序列片段聚集在一起,而Jeju中这些短序列表现为缺失或存在于不同的位点。连接序列片段的重复序列和重叠序列(由少数几个核苷酸组成)暗示同源重组导致的广泛性重排可能涉及到该区段的序列进化。本研究还利用其他植物种类的线粒体DNA序列进行分析,揭示CMS相关基因DNA区段的共同特征。结论:辣椒CMS和雄性可育系线粒体基因组大部分序列表现出一致性,但存在大量的基因组重排现象。辣椒CMS候选基因位于高度重排的CMS特定DNA区域的边界或重复序列附近。通过对其他物种CMS相关基因的特征分析,揭示出可能涉及到CMS相关基因进化的共同机制。

关键词：线粒体基因组 CMS 结构变异核苷酸测序辣椒全基因组序列 DNA重排胞质雄性不育

The Skin Whitening Effect of Co-Cultured Conditioned Medium: Involvement of Synergy between Stem Cells and Immune Cells

在线全文

学校读者我要写书评

暂无评论

Combination of cell signaling molecules can facilitate MYOD1-mediated myogenic transdifferentiation of pig fibroblasts.

Journal of Cosmetics, Dermatological Sciences and Applications（化妆品、皮肤病及应用期刊） 2021年第4期

作者： Tae-Kyung Ko Hye-Mi Hong dong-Soo Kim Da-Young Yoo Sung hwan hwang Jung-Hwa Kang

来源：评论

学校读者我要写书评

暂无评论

Phytogenic feed additives alleviate pathogenic Escherichia coli-induced intestinal damage through improving barrier integrity and inhibiting inflammation in weaned pigs

畜牧与生物技术杂志(英文版) 2021年第4期

作者： Jinsol Jeong Kwang-hwan Choi Seung-Hun Kim dong-Kyung Lee Jong-Nam Oh Mingyun Lee Gyung Cheol Choe Chang-Kyu Lee

来源：评论

学校读者我要写书评

暂无评论

边缘区淋巴瘤晚期患者R-CVP后利妥昔单抗维持治疗的Ⅱ期研究:一项改善淋巴瘤生存协会(CISL)的研究

畜牧与生物技术杂志(英文版) 2023年第1期

作者： Se Yeon Chang Min Ho Song Ji hwan Lee Han Jin Oh Yong Ju Kim Jae Woo An Young Bin Go dong Cheol Song Hyun Ah.Cho Seung Yeol Cho dong Jun Kim Mi Suk Kim Hyeun Bum Kim Jin Ho Cho

来源：博看期刊评论

在线全文

博看期刊

学校读者我要写书评

暂无评论

癌症 2020年第3期39卷 118-128页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok‑hwan Yang Won Sik Lee Hyo Jung Kim Ho‑Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung‑Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong‑Won Lee Jae Hoon Lee Ho Sup Lee Ho‑Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa‑guSeoul 05505Republic of Korea Department of Hematology‑Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology‑Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多... 详细信息

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多中心、单臂、开放标签的Ⅱ期研究评估了对一线R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone;利妥昔单抗、环磷酰胺、长春新碱和泼尼松龙)治疗有反应的Ⅲ–Ⅳ期CD20阳性MZL患者进行利妥昔单抗维持治疗2年的生存率。本研究旨在明确R-CVP后利妥昔单抗维持治疗的策略是否有进一步研究的价值。方法在利妥昔单抗维持治疗之前,Ⅲ–Ⅳ期MZL患者应接受6–8周期的R-CVP一线治疗。每个周期为3周,第1 d静脉输注利妥昔单抗(375 mg/m^2)、环磷酰胺(750 mg/m^2)和长春新碱(1.4 mg/m^2;最大2 mg),第1–5 d口服泼尼松龙(100 mg)。对R-CVP治疗达到完全缓解(complete response,CR)、部分缓解(part response,PR)或疾病稳定(stable response,SD)的患者进行利妥昔单抗维持治疗,每8周静脉注射利妥昔单抗375mg/m^2,直到12个周期。主要终点为无进展生存期(progression-free surviva,PFS),次要终点为总生存期(overall survival,OS)和治疗安全性。结果共纳入47例患者,其中45(96%)例接受了利妥昔单抗维持治疗。15(33%)例患者有淋巴结MZL。在进行R-CVP一线治疗后,分别有20(44%)例、22(49%)例和3(7%)例的患者达到了CR、PR和SD。中位随访38.2个月后,患者的3年PFS率为81%。在利妥昔单抗维持治疗期间,R-CVP治疗后有6例PR和1例SD患者获得CR。LDH升高和B症状是PFS的重要预后因素(P=0.003),3年OS率为90%。利妥昔单抗维持治疗的耐受性良好,常见的治疗性不良事件为感觉性神经病(18%)、肌痛(13%)、疲劳(9%)和中性粒细胞减少(9%)。结论一线R-CVP治疗后利妥昔单抗维持治疗在Ⅲ–Ⅳ期MZL患者中不仅表现出较好的PFS,而且药物毒性反应评价良好。

关键词：边缘区淋巴瘤晚期利妥昔单抗环磷酰胺长春新碱维持多中心开放标签生存